Up | AC
What's New | AC Home
Food and Drug Administration
Oncologic Drugs
Advisory Committee
March 13, 2006
MORNING SESSION
Briefing Information
Food and Drug Administration
Disclaimer
Portions of these documents may have been
determined to be exempt from disclosure under the Freedom of
Inoformation Act (the FOIA) (5 U.S.C. §552). These redacted
portions will appear as white space on the screen or on the
printed page.
FDA
Backgrounder – March 13. (a.m. Session)
AFTERNOON SESSION
Eli Lilly &
Company - Briefing Material
The statements contained
in this document(s) are not those of the FDA, and the FDA does
not necessarily agree with these statements. FDA has not made
a final determination about the issues to be discussed at the
Advisory Committee Meeting.
Gemzar
® Briefing Material
Food and Drug Administration
Disclaimer
Portions of these documents may have been
determined to be exempt from disclosure under the Freedom of
Inoformation Act (the FOIA) (5 U.S.C. §552). These redacted
portions will appear as white space on the screen or on the
printed page.
FDA
Gemzar ® Review
Bibliography
FDA/Dockets Management